New Approaches to the Management of Gram-Negative Resistant Infections
  • CME
  • CE

In this CME/CE/CPE-certified Webcast of a live workshop, expert faculty review best practices in managing multidrug-resistant Gram-negative bacterial infections, with a focus on recently approved and emerging investigational treatment options.
Keith S. Kaye, MD, MPH
Program Director
Jason Pogue Headshot
Jason M. Pogue, PharmD
Michael Satlin Headshot
Michael Satlin, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: November 8, 2018 Expiration: November 7, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the epidemiology and changing patterns of multidrug resistance of Gram-negative bacteria to include local trends and the significance of this information in clinical practice
  • Explore key clinical trial data on new and emerging therapeutic options against multidrug-resistant Gram-negative bacteria, with attention to safety, efficacy, and adverse event profiles of newer agents vs those of established agents of the same class
  • Discuss individualized management approaches to the treatment of multidrug-resistant Gram-negative infections with a focus on next-generation antimicrobial agents and their potential utility for reducing resistance and improving patient-specific administration and dosing considerations

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Keith S. Kaye, MD, MPH

Professor
Division of Infectious Diseases
Department of Internal Medicine
University of Michigan Medical School
University of Michigan Health System
Ann Arbor, Michigan

Keith S. Kaye, MD, MPH, has disclosed that he has received consulting fees from Achaogen, Melinta, Merck, Nabriva, Paratek, Shionogi, The Medicines Company, and Xellia.

Faculty

Jason M. Pogue, PharmD

Clinical Assistant Professor of Medicine
Wayne State University School of Medicine
Clinical Pharmacist, Infectious Diseases
Department of Pharmacy
Sinai-Grace Hospital
Detroit Medical Center
Detroit, Michigan

Jason M. Pogue, PharmD, has disclosed that he has received consulting fees from Achaogen, Allergan, Melinta, Merck, Shionogi, Tetraphase, and The Medicines Company and fees for non-CME/CE services from Allergan, Melinta, and Merck.
Michael Satlin, MD

Associate Professor
Division of Infectious Diseases
Department of Internal Medicine
Weill Cornell Medicine
New York, New York

Michael Satlin, MD, has disclosed that he has received consulting fees from Achaogen and funds for research support from Allergan and Merck.

Staff

Ryan P. Topping, PhD

Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other healthcare providers who care for patients with multidrug-resistant Gram-negative infections.

Goal

The goal of this activity is to improve participants’ knowledge and competence in applying current and emerging antibacterials in the management of patients with resistant Gram-negative infections.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-434-H01-P.

Type of Activity: Knowledge

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 08, 2018, through November 07, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Ruxolitinib plus thalidomide achieved objective disease improvements in patients with myelofibrosis in phase II study from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Results from the CASSINI study of rivaroxaban for VTE prophylaxis in ambulatory patients with cancer from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Results from phase I LEGEND-2 trial of LCAR-B38M CAR T-cell therapy in R/R multiple myeloma from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018

Phase III RV-MM-PI-0752 study on optimizing lenalidomide/dexamethasone for elderly patients with newly diagnosed MM from ASH 2018 reported by Clinical Care Options (CCO).

Released: December 11, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Achaogen, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?